December 21, 2014 6:54 PM ET

Biotechnology

Company Overview of YM BioSciences Inc.

Company Overview

YM BioSciences Inc., a drug development company, engages in developing hematology and cancer-related products. Its products include CYT387, a dual inhibitor of the JAK1 and JAK2 kinases, which has implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis, as well in various other disorders comprising indications in hematology, oncology, and inflammatory diseases. The company is evaluating, CYT387, in a Phase I/II trial and a Phase II trial for the treatment of patients with myelofibrosis, a chronic debilitating disease in which a patient’s bone marrow is replaced by scar tissue. It is also developing nimotuzumab, a humanized monoclonal ...

Building 11

Suite 400

5045 Orbitor Drive

Mississauga, ON L4W 4Y4

Canada

Founded in 1994

32 Employees

Phone:

905-629-9761

Fax:

905-629-4959

Key Executives for YM BioSciences Inc.

Vice President of Finance & Administration
Age: 70
President of Aerolef Division
Age: 56
Head of Regulatory Affairs
Interim Head of Program Management
Principal Regulatory Advisor
Compensation as of Fiscal Year 2014.

YM BioSciences Inc. Key Developments

YM BioSciences Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2012

YM BioSciences Inc. reported unaudited consolidated earnings results for the second quarter and six months ended December 31, 2012. For the quarter, the company reported revenue of CAD 3.9 million compared to CAD 0.4 million for the second quarter of fiscal 2012. Net loss was CAD 11.3 million or CAD 0.07 per basic and diluted share compared to CAD 6.6 million or CAD 0.06 per basic and diluted share for the same period last year. Loss before finance income and finance costs was CAD 5.48 million compared to CAD 8.03 million reported a year ago. Revenue for the first six months of fiscal 2013 was CAD 4.2 million compared to CAD 0.6 million for the first six months of fiscal 2012. The increase was due to the sale of nimotuzumab licenses and subsequent recognition of all remaining deferred revenue relating to nimotuzumab licenses in December 2012. Net loss was CAD 20.0 million or CAD 0.13 per basic and diluted share compared to CAD 7.5 million or CAD 0.06 per basic and diluted share for the same period last year. Loss before finance income and finance costs was CAD 14.4 million compared to CAD 16.43 million reported a year ago. Net cash used in operating activities was CAD 12.97 million compared to CAD 13.74 million reported a year ago. Additions to property and equipment were CAD 18.54 million compared to CAD 10.22 million reported a year ago.

YM BioSciences Inc. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013

YM BioSciences Inc. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013 . Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.

YM BioSciences Inc., Special/Extraordinary Shareholders Meeting, Jan 31, 2013

YM BioSciences Inc., Special/Extraordinary Shareholders Meeting, Jan 31, 2013., at 10:00 US Eastern Standard Time. Location: Gowling Lafleur Henderson LLP. Agenda: To approve the plan of arrangement.

Similar Private Companies By Industry

Company Name Region
Biovar Life Support, Inc. Americas
Soricimed Biopharma Inc. Americas
Qubit Systems Inc. Americas
DPC Biosciences, Inc. Americas
QIAGEN Canada, Inc Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact YM BioSciences Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.